4.4 Review

Metabolic reprogramming in epithelial ovarian cancer

Journal

AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
Volume 13, Issue 9, Pages 9950-9973

Publisher

E-CENTURY PUBLISHING CORP

Keywords

chemoresistance; chemosensitivity; epithelial ovarian cancer; glycolysis; oxidative phosphorylation

Funding

  1. Thailand Science Research and Innovation [MRG62-80014]
  2. National Research Council of Thailand
  3. National Science and Technology Development Agency Thailand
  4. Chiang Mai University Center of Excellence Award

Ask authors/readers for more resources

Cancer cells show adaptations to their metabolism to facilitate growth, invasiveness, and metastasis. While aerobic glycolysis has been thought to be the dominant energy metabolism in cancer, recent data suggest that oxidative phosphorylation may be more likely in some cancer cells, particularly in epithelial ovarian cancer.
Cancer cells usually show adaptations to their metabolism that facilitate their growth, invasiveness, and metastasis. Therefore, reprogramming the energy metabolism is one of the current key foci of cancer research and treatment. Although aerobic glycolysis-the Warburg effect-has been thought to be the dominant energy metabolism in cancer, recent data indicate a different possibility, specifically that oxidative phosphorylation (OXPHOS) is the more likely form of energy metabolism in some cancer cells. Due to the heterogeneity of epithelial ovarian cancer, there are different metabolic preferences among cell types, study types (in vivo/in vitro), and invasiveness. Current knowledge acknowledges glycolysis to be the main energy provider in ovarian cancer growth, invasion, migration, and viability, so specific agents targeting the glycolysis or OXPHOS pathways have been used in previous studies to attenuate tumor progression and increase chemosensitization. However, chemoresistant cell lines exert various metabolic preferences. This review comprehensively summarizes the information from existing reports which could together provide an in-depth understanding and insights for the development of a novel targeted therapy which can be used as an adjunctive treatment to standard chemotherapy to decelerate tumor progression and decrease the epithelial ovarian cancer mortality rate.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available